伴隨診斷聯合研究和許可協議（2010-2024）

Companion Diagnostic Collaboration and Licensing Deals 2010-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告審查了伴隨診斷合作和許可協議，詳細瞭解和分析了公司如何以及為何進行伴隨診斷合作。

介紹
過去幾年的伴隨診斷合約
最活躍的伴隨診斷承包商
伴隨診斷合約：依合約類型
伴隨診斷合約：按治療領域
伴隨診斷合約：按行業部門
伴隨診斷合約條款與條件
- 伴隨診斷合約標題金額
- 伴隨診斷合約預付款
- 伴隨診斷合約的里程碑付款
- 伴隨診斷版稅率

第3章主要伴隨診斷合約

介紹
按價值排名最高的伴隨診斷合同

第 4 章：最活躍的同儕診斷合約公司

介紹
最活躍的同儕診斷承包商
最活躍的伴隨診斷承包商簡介

第5章陪診合約名錄

介紹
配套診斷合約目錄

第 6 章伴隨診斷合約：依技術類型

合約目錄
合約目錄 - 伴隨診斷合約：按公司 (AZ)
合約目錄 - 伴隨診斷合約：依合約類型
合約目錄 - 伴隨診斷合約：按治療領域
定義合約類型
關於Biopharma Research Ltd
目前的合作夥伴
目前協議
目前合作夥伴最近報告的標題

簡介目錄

Product Code: CP2106

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 530 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2010
Browse companion diagnostic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

Trends in companion diagnostic dealmaking in the biopharma industry
Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
The leading companion diagnostic deals by value
Most active companion diagnostic licensing dealmakers
Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
- 2.7.1 Companion diagnostic deals headline values
- 2.7.2 Companion diagnostic deal upfront payments
- 2.7.3 Companion diagnostic deal milestone payments
- 2.7.4 Companion diagnostic royalty rates